This article is more than 5 years old. Information may no longer be current.

A Trial of “Armored” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Issue: April 2019 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1, open-label study testing the safety of different dose levels of specially prepared cells collected from the patient called “modified T cells” to find a safe dose of modified T cells for patients with relapsed or refractory hematologic malignancies that have progressed after standard therapy.